ERBB2 and gastric cancer: For instance, the monoclonal antibodies trastuzumab and pertuzumab targeting human epidermal growth factor receptor 2 (HER2) are currently used in combination with chemotherapy as a standard therapy against HER2-positive breast and gastric cancer [1,2,3].